ID

22834

Descripción

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00477087

Link

https://clinicaltrials.gov/show/NCT00477087

Palabras clave

Versiones (1)
  1. 12/6/17 12/6/17 -
Subido en

12 de junio de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Prostatic Neoplasms NCT00477087

Inglés

Eligibility Prostatic Neoplasms NCT00477087

1 formularios  
Criteria
Descripción

Criteria

must be of age 18 years or older
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
must have histologically confirmed adenocarcinoma of the prostate
Descripción

Adenocarcinoma of prostate

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0007112
must have hormone-refractory prostate cancer
Descripción

Hormone refractory prostate cancer

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1328504
must have failed first-line docetaxel-containing regimen
Descripción

docetaxel | First line treatment failed

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0246415
UMLS CUI [2,1]
C1708063
UMLS CUI [2,2]
C0231175
must not have had any prior immunotherapy including, but not limited to, vaccines and gm-csf
Descripción

Immunotherapy Absent | Vaccines Absent | GM-CSF Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0021083
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0042210
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C0079460
UMLS CUI [3,2]
C0332197
minimum psa > 5mg/dl, and rising according to the psa consensus criteria (i.e. progressive disease after androgen deprivation and during first-line docetaxel-based chemotherapy)
Descripción

Prostate-Specific Antigen Minimum | Raised prostate specific antigen | Progressive Disease Post Androgen suppression | docetaxel | First line treatment Chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0138741
UMLS CUI [1,2]
C1524031
UMLS CUI [2]
C0178415
UMLS CUI [3,1]
C1335499
UMLS CUI [3,2]
C0687676
UMLS CUI [3,3]
C1515985
UMLS CUI [4]
C0246415
UMLS CUI [5,1]
C1708063
UMLS CUI [5,2]
C0392920
kps > 60%
Descripción

Karnofsky Performance Status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0206065
life expectancy of greater than 6 months
Descripción

Life Expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
exclusion criteria:- concomitant hormonal therapy
Descripción

Exclusion Criteria | Hormone Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0279025
noncompliance
Descripción

Non-compliance

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0457432
use of herbal products known to decrease psa levels
Descripción

Medicinal Herbs | Prostatic specific antigen decreased

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0025125
UMLS CUI [2]
C0178414
use of supplements or complementary medicines, except for conventional multivitamin supplements, selenium, lycopene, soy supplements, vitamin e
Descripción

Supplement Use of | Pharmaceutical Preparations Additional | Multivitamin preparation Supplement conventional | Selenium | lycopene | Soy | Vitamin E

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2348609
UMLS CUI [1,2]
C1524063
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1524062
UMLS CUI [3,1]
C0301532
UMLS CUI [3,2]
C2348609
UMLS CUI [3,3]
C0439858
UMLS CUI [4]
C0521939
UMLS CUI [5]
C0065331
UMLS CUI [6]
C2756587
UMLS CUI [7]
C0042874
initiation of bisphosphonates within one month prior to enrollment or throughout the study
Descripción

Diphosphonates

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0012544
any prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment
Descripción

Radiopharmaceuticals | Strontium | Samarium

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0182638
UMLS CUI [2]
C0038467
UMLS CUI [3]
C0036147
major surgery or radiation therapy completed <4 weeks prior to enrollment
Descripción

major surgery | Therapeutic radiology procedure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0679637
UMLS CUI [2]
C1522449
any concomitant second malignancy other than non-melanoma skin cancer
Descripción

Neoplasms, Second | Skin carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0085183
UMLS CUI [2]
C0699893
any concomitant serious infection or nonmalignant medical illness
Descripción

Communicable Disease Serious | Illness Non-Malignant Serious

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205404
UMLS CUI [2,1]
C0221423
UMLS CUI [2,2]
C1518371
UMLS CUI [2,3]
C0205404
anc < 1,500/µl, platelet count <100,000/µl, hemoglobin < 8 mg/dl
Descripción

Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0948762
UMLS CUI [2]
C0032181
UMLS CUI [3]
C0518015
total bilirubin greater than 1.5 x ulrr
Descripción

Elevated total bilirubin

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0741494
alt or ast greater than 2.5 x ulrr if no demonstrable liver metastases or greater than 5.0 x ulrr in presence of liver metastases
Descripción

Alanine aminotransferase increased | Aspartate aminotransferase increased | Secondary malignant neoplasm of liver

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0151905
UMLS CUI [2]
C0151904
UMLS CUI [3]
C0494165
Volver a la parte superior de la página

Similar models

Eligibility Prostatic Neoplasms NCT00477087

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Age
Item
must be of age 18 years or older
boolean
C0001779 (UMLS CUI [1])
Adenocarcinoma of prostate
Item
must have histologically confirmed adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Hormone refractory prostate cancer
Item
must have hormone-refractory prostate cancer
boolean
C1328504 (UMLS CUI [1])
docetaxel | First line treatment failed
Item
must have failed first-line docetaxel-containing regimen
boolean
C0246415 (UMLS CUI [1])
C1708063 (UMLS CUI [2,1])
C0231175 (UMLS CUI [2,2])
Immunotherapy Absent | Vaccines Absent | GM-CSF Absent
Item
must not have had any prior immunotherapy including, but not limited to, vaccines and gm-csf
boolean
C0021083 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0042210 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0079460 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
Prostate-Specific Antigen Minimum | Raised prostate specific antigen | Progressive Disease Post Androgen suppression | docetaxel | First line treatment Chemotherapy
Item
minimum psa > 5mg/dl, and rising according to the psa consensus criteria (i.e. progressive disease after androgen deprivation and during first-line docetaxel-based chemotherapy)
boolean
C0138741 (UMLS CUI [1,1])
C1524031 (UMLS CUI [1,2])
C0178415 (UMLS CUI [2])
C1335499 (UMLS CUI [3,1])
C0687676 (UMLS CUI [3,2])
C1515985 (UMLS CUI [3,3])
C0246415 (UMLS CUI [4])
C1708063 (UMLS CUI [5,1])
C0392920 (UMLS CUI [5,2])
Karnofsky Performance Status
Item
kps > 60%
boolean
C0206065 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of greater than 6 months
boolean
C0023671 (UMLS CUI [1])
Exclusion Criteria | Hormone Therapy
Item
exclusion criteria:- concomitant hormonal therapy
boolean
C0680251 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
Non-compliance
Item
noncompliance
boolean
C0457432 (UMLS CUI [1])
Medicinal Herbs | Prostatic specific antigen decreased
Item
use of herbal products known to decrease psa levels
boolean
C0025125 (UMLS CUI [1])
C0178414 (UMLS CUI [2])
Supplement Use of | Pharmaceutical Preparations Additional | Multivitamin preparation Supplement conventional | Selenium | lycopene | Soy | Vitamin E
Item
use of supplements or complementary medicines, except for conventional multivitamin supplements, selenium, lycopene, soy supplements, vitamin e
boolean
C2348609 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
C0013227 (UMLS CUI [2,1])
C1524062 (UMLS CUI [2,2])
C0301532 (UMLS CUI [3,1])
C2348609 (UMLS CUI [3,2])
C0439858 (UMLS CUI [3,3])
C0521939 (UMLS CUI [4])
C0065331 (UMLS CUI [5])
C2756587 (UMLS CUI [6])
C0042874 (UMLS CUI [7])
Diphosphonates
Item
initiation of bisphosphonates within one month prior to enrollment or throughout the study
boolean
C0012544 (UMLS CUI [1])
Radiopharmaceuticals | Strontium | Samarium
Item
any prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment
boolean
C0182638 (UMLS CUI [1])
C0038467 (UMLS CUI [2])
C0036147 (UMLS CUI [3])
major surgery | Therapeutic radiology procedure
Item
major surgery or radiation therapy completed <4 weeks prior to enrollment
boolean
C0679637 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
Neoplasms, Second | Skin carcinoma
Item
any concomitant second malignancy other than non-melanoma skin cancer
boolean
C0085183 (UMLS CUI [1])
C0699893 (UMLS CUI [2])
Communicable Disease Serious | Illness Non-Malignant Serious
Item
any concomitant serious infection or nonmalignant medical illness
boolean
C0009450 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0221423 (UMLS CUI [2,1])
C1518371 (UMLS CUI [2,2])
C0205404 (UMLS CUI [2,3])
Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement
Item
anc < 1,500/µl, platelet count <100,000/µl, hemoglobin < 8 mg/dl
boolean
C0948762 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
Elevated total bilirubin
Item
total bilirubin greater than 1.5 x ulrr
boolean
C0741494 (UMLS CUI [1])
Alanine aminotransferase increased | Aspartate aminotransferase increased | Secondary malignant neoplasm of liver
Item
alt or ast greater than 2.5 x ulrr if no demonstrable liver metastases or greater than 5.0 x ulrr in presence of liver metastases
boolean
C0151905 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
C0494165 (UMLS CUI [3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial